Alcon Inc. Ordinary Shares

ALC trades at a remarkable 37.96x earnings—nearly double typical healthcare multiples—despite RSI of 40.5 signaling neither overbought nor oversold conditions. The disconnect suggests the market is pricing in substantial future growth or margins expansion, but the valuation leaves minimal room for disappointment. At $38 billion market cap, this is a mature player commanding a premium that feels stretched relative to near-term catalysts. The stock sits comfortably away from 52-week highs, which could indicate consolidation or investor caution about the rich valuation itself. For a pharma-adjacent business, this P/E invites scrutiny around earnings sustainability rather than downside protection.